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AbstrACt
Objectives Children requiring cortisol replacement 
therapy are often prescribed hydrocortisone doses of 
2.5 mg, but as this is commercially unavailable 10 mg 
tablets, with functional break lines, are split commonly in 
an attempt to deliver the correct dose. This study aimed 
to determine the dose variation obtained from quartered 
hydrocortisone tablets when different operators performed 
the splitting procedure and to ascertain whether better 
uniformity could be attained from mini-tablets as an 
alternative formulation.
Methods Hydrocortisone 10 mg tablets were quartered 
by four different operators using a standard pill splitter. 
Hydrocortisone 2.5 mg mini-tablets (3 mm diameter) 
were formulated using a wet granulation method and 
manufactured using a high-speed rotary press simulator. 
The weight and content uniformity of the quartered 
tablets and mini-tablets were assessed according 
to pharmacopoeial standards. The physical strength 
and dissolution profiles of the mini-tablets were also 
determined.
results More than half of all quartered 10 mg tablets 
were outside of the ±10% of the stated US Pharmacopoeia 
hydrocortisone content (mean 2.34 mg, SD 0.36, 
coefficient of variation (CV) 15.18%) and more than 
40% of the quartered tablets were outside the European 
Pharmacopoeia weight variation. Robust mini-tablets 
(tensile strengths of >4 MPa) were produced successfully. 
The mini-tablets passed the pharmacopoeial weight 
and content uniformity requirements (mean 2.54 mg, SD 
0.04, CV 1.72%) and drug release criteria during in vitro 
dissolution testing.
Conclusion This study confirmed that quartering 10 mg 
hydrocortisone tablets produces unacceptable dose 
variations and that it is feasible to produce 3 mm mini-
tablets containing more accurate doses for paediatric 
patients.
IntrOduCtIOn
Hydrocortisone is the preferred cortisol 
replacement therapy in childhood, because 
it is of lower potency than the synthetic 
glucocorticoids and may be associated with 
fewer side effects.1 Hydrocortisone doses of 
8 mg/m2/day,2 given in three to four divided 
doses, are thought to be adequate for cortisol 
replacement therapy in childhood. Higher, 
supraphysiological doses of 10–15 mg/m2/
day are used to treat patients with congenital 
adrenal hyperplasia (CAH),3 in whom the 
goal of treatment is to achieve suppression 
of adrenocorticotropic hormone (ACTH) 
drive to the adrenal gland, while avoiding the 
adverse effects of glucocorticoid excess.
Liquid hydrocortisone formulations, such 
as a 1 mg/mL oral suspension, are only avail-
able as unlicensed specials and in addition to 
the general limitations of transport, storage 
and stability there are potential concerns 
relating to the bioavailability of liquid 
hydrocortisone formulations.4 In paediatric 
practice, 2.5 mg hydrocortisone doses are 
prescribed frequently and to achieve these 
doses, it is recommended that tablets are 
divided or crushed.3 Crushing and dissolving 
tablets may result in unacceptably high vari-
ability of dosing2 3 and it may be preferable 
to quarter 10 mg tablets. The hydrocortisone 
10 mg tablets licensed for oral administra-
tion are quarter scored, allowing them to be 
What is already known on this topic?
 ► Children often require a hydrocortisone dose 
of 2.5 mg but there is no suitable, licensed, 
formulation available.
 ► Hydrocortisone 10 mg tablets, with functional break 
lines, are split commonly in an attempt to deliver 
the correct dose.
 ► Mini-tablets are an alternative and acceptable oral 
dosage form for children as young as 6 months old.
What this study hopes to add?
 ► Quartering 10 mg hydrocortisone tablets produces 
unacceptable dose variations.
 ► Additional variability in dosing could be introduced 
by different operators.
 ► It is feasible to produce 3 mm hydrocortisone mini-
tablets that meet pharmacopoeial requirements of 
weight and dose uniformity.
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divided into equal halves or quarters.5 However, despite 
the presence of functional break lines, splitting may 
result in unequal parts thereby producing unequal doses 
and loss of mass due to crumbling.6
To date, most data relating to the medium-term/long-
term outcomes of children with CAH report features 
more likely to represent over, rather than under, dosing: 
obesity, insulin resistance, elevated leptin levels, dyslipi-
daemia and impaired glucose metabolism.7–10 However, 
working memory performance is lower in children with 
CAH than in unaffected relatives,11 and health-related 
quality of life is also reported to be reduced, with boys 
and girls equally affected, suggesting that this is not 
simply related to androgen excess in girls and associated 
disorders of sex development.12 Erratic and inadequate 
doses of hydrocortisone may contribute to these adverse 
effects.
No current licensed oral hydrocortisone formulation 
adequately meets the dosing requirements of children. 
Mini-tablets provide an alternate to standard tablets 
and oral liquids mainly for paediatric patients, ≥4 years 
of age. Variations exist in the defined size of mini-tab-
lets in literature, but a diameter of ≤3 mm is commonly 
compatible with paediatric patients.13 Mini-tablets can be 
administered to paediatric patients as young as 6 months 
old with their food/beverages and recent studies have 
demonstrated mini-tablets to be more acceptable than 
oral syrups.14–16
AIMs And ObjeCtIves
The aim of this study was to manufacture 3 mm mini-tab-
lets to provide a 2.5 mg dose of hydrocortisone and to 
compare the content uniformity of the mini-tablets 
against quartered hydrocortisone tablets. The content 
uniformity of hydrocortisone mini-tablets and the quar-
ters of commercial hydrocortisone tablets was also deter-
mined. The tensile strength of the mini-tablets and their 
compliance with the pharmacopoeial tests for dissolution 
and uniformity of mass were also assessed.
MAterIAls And MethOds
Materials
Hydrocortisone (10 mg) tablets (Auden Mckenzie 
Pharma Division, UK) were used for the dose uniformity 
study. Analytical grades of hydrocortisone (Sigma Aldrich, 
UK); water (Liverpool John Moores University, Liver-
pool, UK); Methanol (Sigma Aldrich) and Acetonitrile 
(Fischer Scientific UK, Loughborough, UK) were used 
for high-performance liquid chromatography (HPLC) 
analysis.
Mini-tablets were manufactured using hydrocorti-
sone European Pharmacopoeia (Ph. Eur.; Courtin and 
Warner, UK), Microcrystalline cellulose (Avicel PH101; 
FMC, Brussels, Belgium), lactose (Pharmatose 200M; 
DFE Pharma, Goch, Germany), hydroxypropyl methyl 
cellulose 603 (Shin-Etsu Chemicals, Tokyo, Japan), 
croscarmellose sodium (Ac-Di-Sol; FMC Europe NV, 
Brussels, Belgium), silicon dioxide (Aerosil 200; Degus-
sa-Hüls AG, Frankfurt, Germany) and magnesium stea-
rate (BDH Laboratory Supplies, Poole, UK).
Formulation and manufacture of mini-tablets
The mini-tablet formulation was prepared using a wet 
granulation technique to ensure uniformity of die fill, 
since adequate flowability of a formulation is essential for 
the manufacture of mini-tablets due to the small size of 
the die orifice.17 All of the excipients listed in table 1 (with 
the exception of the glidant (Aerosil) and the lubricant 
(magnesium stearate) were blended with hydrocortisone 
for 5 min using a Turbula Shaker Mixer type 2C (Willy 
A. Bachofen, Basel, Switzerland) at 42 rpm. The blended 
powder mixture was then transferred to a Model KM330 
series planetary mixer (Kenwood, UK). Water (0.48 mL 
per g of powder) was added uniformly during mixing by 
spraying with an atomiser from a distance of 10–15 cm 
from the powder bed over a period of 15 min. The wet 
powder mass was screened evenly onto a flat, stainless steel 
tray and oven-dried overnight at 40°C. Dry granules were 
screened using a 1 mm aperture sieve prior to separation 
into size fractions using a laboratory shaker (Endecotts, 
UK). Granules in the size range 125–355 µm were subse-
quently blended with glidant (5 min) and lubricant (2 
min) using the Turbula Shaker Mixer. The bulk density 
(ρB) of the granules in the size range of 125–355 µm was 
determined by filling a measuring cylinder with a known 
weight of granules. The tapped density (ρT) was deter-
mined by dropping the volumetric cylinder 250 times 
from a height of 2.5 cm using a dropbox. The tapping 
procedure was repeated until there was no change in the 
volume of the granule giving the tapped density. The % 
Carr’s Compressibility Index (equation 1) and Hausner 
ratio (equation 2), both indicators of flowability18 in 
fluencing key tablet parameters such as mechanical 
strength and weight uniformity, were calculated.
 Carr
′s
(
%
)
= ρT−ρBρT × 100 (1)
 Hausner Ratio =
ρT
ρB  (2)
The mini-tablets were produced using a Stylcam 
100R rotary press simulator (Medel’Pharm, Beynost, 
France) fitted with 3 mm flat-faced, single-tip tooling 
at a speed of 20 rpm. A compression force of 1–2 kN 
Table 1 Composition of the mini-tablets
Component % per batch
Hydrocortisone 16.67
Microcrystalline cellulose 22.40
Lactose monohydrate 51.60
Hydroxypropyl methyl cellulose 3.00
Croscarmellose sodium 5.00
Colloidal silicon dioxide 0.33
Magnesium stearate 1.00
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(compression pressure of 140–280 MPa) was maintained 
with a fill height of 7.10 mm.
tensile strength
The dimensions of 10 mini-tablets were measured using 
a digital micrometer (Mitutoyo, Tokyo, Japan) and their 
crushing strengths were determined with a 6D Tablet 
Tester (Schleuniger, Germany). Values were used to 
calculate the tensile strength, σ, using equation 3,19 
where P is the crushing strength (N), D is the diameter 
(mm) and T is the tablet thickness (mm).
 σ = 2PpiDT  (3)
Content uniformity analysis of hydrocortisone tablets and 
mini-tablets
An Agilent 1200 series with Variable Wavelength Detector 
(Agilent Technologies, UK) set to 254 nm was used with 
a 4.6 mmx15 cm column containing 5 µm packing of 
octadecyl silane chemically bonded to porous silica 
(Phenomenex, HyperClone 5µ ODS C18). The mobile 
phase (degassed 50:25:25 mixture of water, acetonitrile 
and methanol) flow rate was 1 mL/min and an injection 
volume of 10 µL was used. Chemstation open lab CDS 
software for LC and LC-MS Rev C.01.05 (Agilent Tech-
nologies) were used for all data analysis.
Standard solutions of hydrocortisone (0%–0.2% 
w/v) were prepared and filtered into HPLC vials using 
a 0.45 µm PTFE filter (Agilent Technologies) and 5 mL 
syringe. The peak area–concentrations response was 
acceptably linear (R2=0.9985), and thus a 0.01% w/v 
was used as a single-point calibration for the assays. The 
retention time of hydrocortisone was 4.0 (±0.2) min. The 
active content of whole hydrocortisone 10 mg tablets was 
determined by weighing and dispersing individual tablets 
into 100 mL mobile phase by sonification. Each tablet 
was analysed in duplicate. The hydrocortisone content of 
quartered tablets was determined, each individual tablet 
was weighed and, using a Deluxe Pill Splitter (W+W 
Medsystems, UK), cut into quarters. Each quarter was 
weighed and dispersed into 25 mL mobile phase by soni-
fication. Each tablet quarter was analysed in duplicate. 
Four individuals each quartered five tablets to account 
for interoperator variability. The operators, comprising 
two students and two academics, had no previous experi-
ence of tablet splitting. The quarters were then weighed 
and assayed.
The active content of the 2.5 mg hydrocortisone 
mini-tablets was determined by weighing and dispersed 
individual mini-tablets into 25 mL mobile phase by sonifi-
cation. As per US Pharmacopoeia (USP) 905 (uniformity 
of dosage units), 10 whole mini-tablets were analysed per 
batch.20 Each mini-tablet was analysed in duplicate. All 
solutions were filtered into HPLC vials using a 0.45 µm 
PTFE filter (Agilent Technologies) and 5 mL syringe 
prior to analysis.
According to USP (905)  uniformity of dosage units, 
the acceptance value (AV) is calculated using equation 4, 
where X is the sample mean as a % of label claim, k is 2.4 
for L1 criteria and s is the SD of the sample.20 M is depen-
dent on the sample mean and if X ≥98.5% and ≤101.5% 
of the label claim then M=X and, as in the present study, 
(M–X) becomes zero. The L1 criteria states that 10 
samples should be tested and the AV should be ±15%.20
 Aceptance Value =
(
M− X) + ks (4)
Weight uniformity analysis of hydrocortisone tablets and 
mini-tablets
The Ph. Eur. monograph ‘Uniformity of mass of single-
dose preparations’ method21 was employed to determine 
the uniformity of weight of the 2.5 mg mini-tablets, and 
quartered 10 mg hydrocortisone tablets. Twenty tablets 
and mini-tablets were weighed individually and their 
mean weights calculated. The products failed if >2 of 
the individual tablets’ weight deviated by more than 
10% (mini-tablets) or 7.5% (tablets) from the average 
weight and if one tablet weight deviated by >20% 
(mini-tablets) or 15% (tablets) from the average weight.21 
For quartered tablets, the mean weight was calculated 
and the percentage of samples that failed to meet the 
same weight variation criteria as mini-tablets was calcu-
lated.
drug release from hydrocortisone mini-tablets
The dissolution method from USP monograph for 
hydrocortisone tablets was used,22 using a Varian VK 7010 
dissolution apparatus (Agilent Technologies) attached to 
UV spectrophotometer (Cary 50 UV spectrophotometer) 
at 248 nm. USP apparatus 2 (paddle apparatus), with a 
paddle speed of 50 rpm and 900 mL of water as the disso-
lution media (at 37°C) were used for the test.23
statistical analysis
The weight and content uniformity of tablet quarters 
(data were normally distributed) were compared by 
one-way analysis of variance using the Minitab V.17.1.0 
statistical software package (Minitab, USA). A P value 
of less than 0.05 was considered significant. Regression 
analysis was used to determine the correlation coefficient 
(R2 value) between weight and content of quartered 
hydrocortisone tablets.
results
splitting of hydrocortisone tablets
The tablets used for the study were convex, diamond 
shaped and quarter scored allowing them to be divided 
into equal halves or quarters.5 The assay of the whole 
hydrocortisone tablets gave >98% recovery, which is 
within the specified 90%–110% limits of the USP mono-
graph for hydrocortisone tablets.22 The mean weight of 
whole hydrocortisone tablets was 244.18 mg (SD 1.70 mg, 
coefficient of variation (CV) 0.7%).
The recovered weights of the quartered tablets indi-
cated that approximately 2% mass was lost during the 
subdivision process. The expected weight for each tablet 
quarter was 61.05 mg, based on the mean whole tablet 
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weight. The obtained weight was 59.83 mg (SD 8.45 mg). 
However, 33 of the 80 (41%) quartered tablets failed to 
meet the Ph. Eur. monograph specification.21 Based on 
the mean mass of 59.83 mg, the criteria would allow quar-
tered tablets to have a mass in range 53.85–65.81 mg.
The mean content of hydrocortisone in all of the quar-
tered tablets (n=80) was 2.34 mg (94% of 2.5 mg target 
dose), with a CV of 15%, range 1.28 (51%) to 3.39 mg 
(136%). Of the 80, 43 quartered tablets (54%) failed to 
achieve ±10% (2.25–2.75 mg) of the target 2.5 mg dose.
Figure 1 shows the correlation between quartered 
tablet weight and hydrocortisone content, which explains 
the large number of substandard hydrocortisone doses in 
the quarters, as content is directly related to weight.
Operator bias
The data obtained by the four individual operators 
when performing the tablet quartering is summarised 
in table 2. Although there was no significant difference 
in the mean weights (P=0.206) or mean hydrocortisone 
content (P=0.253) of the quartered tablets produced by 
the different operators, there were marked differences in 
the ranges obtained. All four operators produced quar-
tered tablets outside of the weight variation limits spec-
ified. Splitting by operator A resulted in a mean hydro-
cortisone content of 2.40 mg (96% of the target dose) 
but had the largest variation between the quantities; 
51%–136% of the target 2.5 mg dose per quarter. Opera-
tors B and C obtained a mean quarter content of 2.23 and 
2.22 mg (89% of 2.5 mg target dose), respectively, and 
operator C had a much narrower range for the hydro-
cortisone content in quartered tablets at 78%–103%. 
Operator D on the other hand obtained a mean hydro-
cortisone content of 2.51 mg (100.4% of target) but the 
range was relatively high at 73%–124% of the target dose. 
The mean hydrocortisone contents for operators B and 
C were outside of the ±10% limit stated in the USP.20 In 
addition to this, each of the operators had individual 
quarters that had hydrocortisone contents outside of the 
±10% limit.
Mini-tablets
Hydrocortisone mini-tablets were manufactured success-
fully under simulated rotary press production condi-
tions. The tapped density of granules used for the manu-
facture of the mini-tablets was determined as 0.48 g/mL 
and the Carr’s Index value of 16% and Hausner ratio of 
1.19 indicated a fair flowability. The Stylcam is a high 
precision, single station press capable of producing up 
to 2400 tablets per hour using an automatic feeder oper-
ates using a mechanical cam, which produces a biaxial 
compaction profile analogous to that of a rotary tablet 
press.
Although mini-tablets were produced at a relatively 
high compression speed of 20 rpm (equivalent to a rotary 
press production rate of approximately 80 000 tablets per 
hour24), the flow of the granules from the hopper into 
the narrow die orifice during manufacture was satisfac-
tory and all mini-tablets met the pharmacopoeial spec-
ification for uniformity of mass.21 Consistent and high 
tensile strengths were also achieved throughout the batch 
as shown in table 3, indicating a good compactibility of 
the granules. Figure 2 illustrates that hydrocortisone was 
released rapidly and consistently from mini-tablets under 
in vitro dissolution conditions. The full dose was released 
within 10 min from all mini-tablets, thus passing the 
dissolution specification for immediate release dosage 
forms.23
Content uniformity analysis carried out on 10 
mini-tablets gave an AV of 4.37% when using equation 
4, thus meeting the USP (905)  Uniformity of Dosage 
L1 criteria. Furthermore, mini-tablets obtained a mean 
hydrocortisone content of 2.54 mg (101.68% of target 
dose) which is compliant to the USP.22 These weight and 
content uniformity data for hydrocortisone mini-tab-
lets demonstrate clear superiority over quartered 10 mg 
hydrocortisone tablets and, unlike manipulated tablets, 
mini-tablets did not fail compliance with any of the USP 
requirements.
Figure 1 Correlation between weight and content of 
quartered hydrocortisone tablets.
Table 2 Weight and content uniformity of hydrocortisone tablet quarters (n=20 for each operator)
Operator Mean weight, mg (SD) CV (%) Range (mg) Mean hydrocortisone content, mg (SD) CV (%) Range (mg)
A 59.67 (11.49) 19.26 31.00–83.90 2.40 (0.46) 19.06 1.28–3.39
B 60.18 (8.63) 14.34 44.20–73.40 2.23 (0.31) 13.92 1.67–2.71
C 60.14 (4.39) 7.30 54.30–69.00 2.22 (0.18) 7.95 1.95–2.57
D 59.33 (8.38) 14.13 42.50–74.00 2.51 (0.36) 14.23 1.84–3.11
CV%, coefficient of variation.
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dIsCussIOn
The availability of age-appropriate medicines for chil-
dren as solid dosage forms remains a pressing need. The 
European Medicines Agency (EMA) Paediatric Commit-
tee’s Formulation Working Group recommends that for 
younger patients, those aged 6–8 years, tablets of 6–7 mm 
with appropriate shape are acceptable.25 Growing 
evidence suggests that some children may have already 
acquired the ability to swallow tablets from an earlier age 
or can be taught using behavioural training interven-
tions, especially those with severe diseases,26 such as chil-
dren with HIV as young as 3 years who were prescribed 
stavudine as a solid dosage form.27
There is limited evidence to support the use of dosage 
from manipulation to obtain an intended dose in paedi-
atric practice.28 A study in UK hospitals reported that in 
paediatric practice, 42%–62% of manipulations involved 
tablets and 6% of total manipulations were steroid 
drugs.29 In the absence of an age-appropriate solid dosage 
form of hydrocortisone, parents/carers, young people 
and healthcare professionals are required to manipulate 
10 mg tablets to derive an intended dose for use in paedi-
atric practice. The data presented in this report clearly 
demonstrate that children treated with 2.5 mg doses of 
hydrocortisone derived from quartered 10 mg tablets 
are subject to unacceptable variability in hydrocortisone 
doses.
While minor fluctuations in doses may be of little signif-
icance, as hydrocortisone pharmacokinetics are influ-
enced by a number of factors, including fasting status30 
puberty31 and the time of day,32 the lowest doses obtained 
from quartered tablets may be associated with symptoms 
of cortisol deficiency, and in patients with CAH, loss of 
ACTH suppression.
As hydrocortisone doses are reduced in a drive to 
address the long-term morbidity associated with gluco-
corticoid excess, the margin for error in dosing is lower, 
and patients are at increased risk for the adverse effects 
of underdosing due to formulation issues.
Clinical markers of glucocorticoid excess, such as 
slow growth or excess weight gain, require observation 
over an extended period, while features of cortisol 
insufficiency, such as tiredness, nausea or poor concen-
tration may be subjective and difficult to assess in the 
young child. For this reason, some clinicians advocate 
the use of 24-hour profiles of cortisol and, in patients 
with CAH, 17α-hydroxyprogesterone (17-OHP) as a 
tool to determine the adequacy of treatment, and to 
titrated doses. However, the application of the data 
obtained from these studies relies on the assumption 
that hydrocortisone doses are reliable and reproducible 
over time. Clearly, this is not the case during treatment 
with quartered 10 mg tablets and this unpredictability 
makes interpretation of clinical symptoms or biochem-
ical measures unreliable and dose titration and optimi-
sation extremely difficult.
The Ph. Eur. monograph21 states that a 10% deviation 
from the mean mass is allowed for tablets weighing ≤80 mg 
is allowed with no more than 2 out of the 20 individual 
masses deviating from the mean mass by 10%. Based 
on the mean mass of 59.83 mg, the criteria would allow 
quartered tablets to have a mass in range 53.85–65.81 mg. 
However, 33 of the 80 (41.25%) quartered tablets failed 
to meet this specification.
This signifies the importance of the technique 
employed during tablet splitting, as there will be inevi-
tably variation from person to person during the oper-
ation. Given the relationship between quartered tablet 
weight and hydrocortisone content (figure 1), it is unsur-
prising that the coefficients of variation for these data are 
very similar (table 2).
In a recent study,33 8 mm tablets were halved and 
their weight variation was compliant with pharmaco-
poeial standards, but the tablets were split by an expe-
rienced pharmacist while in reality the process may not 
always be performed by a qualified healthcare profes-
sional. For example, parents or carers may be required 
to split tablets on a regular basis and the data in this 
study highlight the variations, which could be obtained 
if an untrained operator performs the subdivision of 
doses. Other previous studies have also highlighted the 
Table 3 Weight (n=20), strength and content (n=10) of 3 mm hydrocortisone mini-tablets
Mean weight, mg 
(SD) CV (%)
Mean tensile 
strength, MPa (SD)
Mean content, 
mg (SD)
Mean content as a percentage of 
2.5 mg target dose (%) CV (%)
16.40 (0.64) 3.93 4.45 (0.50) 2.54 (0.04) 101.68 1.72
CV%, coefficient of variation.
Figure 2 Hydrocortisone release from mini-tablets in water 
at 37°C (mean±SD, n=6).
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potential interoperator variation obtained when split-
ting scored tablets.34 35
It is not possible to replicate the physiological, diurnal 
pattern of cortisol secretion using standard formula-
tions of hydrocortisone, and patients experience highly 
non-physiological cortisol profiles, with periods when 
cortisol concentrations are excessively high, shortly 
after a dose of hydrocortisone and prolonged periods 
of hypocortisolaemia between doses.36 37The half-life of 
hydrocortisone is short, requiring three to four doses a 
day, and concordance with treatment can be particularly 
difficult during adolescence. A future aim should be to 
produce alternative modified-release dosage forms to 
provide more consistent and tailored hydrocortisone 
release profiles, and a reduced frequency of dosing.
COnClusIOns
This study confirms that quartering of 10 mg hydro-
cortisone tablets by untrained operators produces an 
unacceptable variation in the weight of the quartered 
segments with 41% of the quartered tablets failing to 
meet the weight variation limits. In addition, 54% of 
the quartered tablets were outside of the ±10% stated 
active pharmaceutical ingredient (API) content (2.5 mg 
for the quartered tablets) proving that under and over 
dosing is a major risk in formulations manipulated 
in this way. The feasibility of industrial production of 
3 mm mini-tablets with allowing delivery of more accu-
rate doses of hydrocortisone than quartered tablets has 
been demonstrated.
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